July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
28 citations
,
January 2010 in “Biological & pharmaceutical bulletin” This study identified that rose, thyme geraniol, palmarosa, and tolu balsam essential oils activate TRPV1, with citronellol and geraniol as newly recognized agonists.
88 citations
,
April 2012 in “Journal of Investigative Dermatology” This study suggests that TRPV3 may play a key role in dry skin-related itch, indicating potential for TRPV3 antagonists in treating pruritus resistant to histamine H1R antagonists.
7 citations
,
April 2015 in “Journal of biological chemistry/The Journal of biological chemistry” This study reports the development of a novel protocol to purify human TRPV3 ion channels, revealing functional properties and differences in ligand interactions, enabling further structural and functional research.
14 citations
,
February 2024 in “Biomolecules” This review explores the role of transient receptor potential vanilloid channels in the pathogenesis of osteoarthritis but reports no new clinical results.
24 citations
,
February 2022 in “Journal of Biological Chemistry” This study found that carvacrol activates the TRPV3 ion channel by binding to a specific pocket formed by the S2-S3 linker, providing insight into its role in skin sensitization and potential for designing specific modulators.
13 citations
,
December 2009 in “Journal of the Peripheral Nervous System” This laboratory study concluded that TRPA1 and TRPV1 channels do not play a role in mechanotransduction processes in slowly adapting type II mechanoreceptors in isolated rat sinus hair follicles.
October 2023 in “Naunyn-Schmiedeberg's Archives of Pharmacology” Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
1 citations
,
September 2025 in “Pediatric Dermatology” This systematic review reported that habit reversal training showed the most consistent benefit for treating pediatric trichotillomania, while evidence for pharmacological treatments and alternative therapies like N-acetylcysteine remains insufficient, highlighting the need for early behavioral intervention and further research into standardized treatment protocols.
January 2024 in “OPAL (Open@LaTrobe) (La Trobe University)” In this study, researchers explored various aspects of the TRPV3 ion channel, including its novel mechanosensitivity to shear stress, and identified novel agonists while investigating how repeated stimulation affects TRPV3 activity, but found no evidence of GPCRs sensitizing the channel.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” This review discusses the development and potential therapeutic applications of adenosine receptor agonists and positive allosteric modulators, noting that while many clinical trials have been unsuccessful, initial results for new compounds are promising.
105 citations
,
August 2010 in “Pharmacology & therapeutics” This article explores the potential of formyl-peptide receptor 2 agonists as innovative anti-inflammatory drugs, highlighting their ability to mimic the body's natural inflammation response, but it presents no new clinical findings.
10 citations
,
April 1964 in “Journal of the American Geriatrics Society” This article reviews triamcinolone acetonide as an intramuscular long-acting steroid therapy for dermatologic disorders but reports no new clinical results.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” In this study of a postmenopausal woman with hyperandrogenism, GnRH agonist treatment significantly reduced testosterone levels, suggesting the androgen excess was ovarian in origin and indicating the potential of using GnRH agonists as a conservative treatment option when surgery is not feasible.
26 citations
,
August 2018 in “Journal of Investigative Dermatology” This study found that TRPV3 activation in human sebocytes inhibits lipid synthesis and triggers proinflammatory cytokine expression, suggesting a role in the pathogenesis of dry skin-associated inflammatory dermatoses.
52 citations
,
January 2005 in “PubMed” This study concluded that alpha(1)-adrenoceptor antagonists are more effective than finasteride in the short term for reducing symptoms of lower urinary tract symptoms associated with benign prostatic hyperplasia.
1 citations
,
December 2014 in “Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology” This study reports that a 15-year-old with trichotillomania showed improvement with aripiprazole treatment, though no consensus on treatment exists in the literature.
This study will explore whether combination therapy with either dutasteride or finasteride and an α1 blocker is more effective than monotherapy for treating BPH, but it reports no new results.
3 citations
,
March 2012 in “Arab Journal of Urology” This study found that cromakalim and pinacidil significantly inhibited porcine detrusor muscle contractions, suggesting these ATP-sensitive potassium channel openers may have potential in treating certain bladder diseases.
65 citations
,
December 2010 in “Current Pharmaceutical Biotechnology” This review explores the diverse roles of TRPV1, emphasizing its involvement in both pain and non-pain-related functions, but reports no new clinical results.
22 citations
,
January 2018 in “European urology focus” This review discusses recent advancements and new approvals in the medical treatment of lower urinary tract symptoms, particularly highlighting drugs for nocturia and ongoing trials for multiple related conditions, while reporting no new clinical results.
69 citations
,
October 2013 in “Journal of Clinical Psychopharmacology” This study found that naltrexone did not significantly reduce hair pulling in adults with trichotillomania compared to placebo, although it improved cognitive flexibility.
January 2019 in “Oncogen” This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
January 2022 in “Drugs of Today”
2 citations
,
October 2022 in “Current Allergy and Asthma Reports” This review outlines the various adverse reactions to biologic therapies in Allergy/Immunology, emphasizing the clinical and management challenges due to overlapping reaction phenotypes and the need for more refined diagnostic and management strategies.
February 2023 in “European Journal of Medical Research” This study identified several drugs that may be potential candidates for repurposing as anti-hyperhidrosis treatments, based on their association with hypohidrosis or anhidrosis in the FDA Adverse Event Reporting System.
10 citations
,
December 2024 in “Allergy” This study found that tralokinumab effectively reduced the severity of moderate-to-severe atopic dermatitis over 28 weeks in adults, with significant improvements in clinical outcomes and biological markers, although 27.4% of patients discontinued treatment due to adverse events or ineffectiveness.
July 1994 in “Annals of Pharmacotherapy” Cromolyn sodium's effectiveness for treating asthma in children under 2 is unclear, possibly more beneficial for older children, and further research is needed.
61 citations
,
September 2010 in “Fitoterapia” This study found that the EtOAc extract of Tridax procumbens aerial parts significantly inhibited rat paw edema and COX enzyme activity, suggesting its potential anti-inflammatory properties.